search
Back to results

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

Primary Purpose

Depression

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Ketamine
Cognitive Behavioral Therapy (CBT)
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • suffering from a depressive episode (DSM 5; either Major Depressive Disorder or Bipolar Disorder) and having failed one or more standard antidepressant treatments during the current episode;
  • Age 18-65;
  • Hamilton Depression Rating Scale (17-HAM-D) score of 21 or more prior to study entry.

Exclusion Criteria:

  • Any Axis I or Axis II Disorder, which at screening is clinically predominant to their depressive episode or has been predominant to their depressive episode at any time within 6 months prior to screening;
  • Active suicidal thoughts with a plan; current or recent (<6 months ago) substance use disorder;
  • Non-affective psychosis (such as schizophrenia or schizoaffective disorder);
  • Pregnancy or breastfeeding;
  • Inability to speak English fluently;
  • A clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results;
  • A history of CBT treatment in the past 12 months;
  • Dementia;
  • Delirium;
  • Any other neurological or mental disease that might affect cognition or the ability to meaningfully participate in CBT.
  • Untreated hypertension as defined by a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening on two of three measurements.
  • Recent myocardial infarction (within one year)
  • Syncopal event within the past year.
  • Congestive heart failure (CHF) New York Heart Association Criteria >Stage 2
  • Angina pectoris.
  • Heart rate <50 or >105 beats per minute at screening

Females are eligible provided they meet criteria A or B below:

  1. Non-childbearing potential: e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening; or
  2. Childbearing potential, and meets the following criteria:

i. Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent.

ii. Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at enrollment prior to receiving study treatment.

iii. Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline.

Sites / Locations

  • Connecticut Mental Health Center
  • Yale Psychiatric Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Ketamine/CBT Group

Arm Description

Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.

Outcomes

Primary Outcome Measures

Extinction Learning Task performance
Hopkins Verbal Learning Test and extinction learning tasks will be administered both one week before and 24-hours after the first ketamine infusion and the change in scores compared.

Secondary Outcome Measures

Montgomery-Asberg Depression Rating Scale (MADRS)
Change in MADRS from baseline through week eight using a random effects model

Full Information

First Posted
November 4, 2014
Last Updated
February 27, 2017
Sponsor
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT02289248
Brief Title
Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine
Official Title
Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Subjects with depressive episodes will be recruited to undergo a brief 2 week course of IV infusions of ketamine in combination with cognitive behavioral therapy for 8 weeks.
Detailed Description
Twelve subjects with current diagnosis of depressive episode will be recruited to undergo a brief course of 4 intravenous infusions of ketamine, given twice weekly for two weeks in combination with CBT, given twice weekly. The CBT course will be 16 total sessions (given over 8 weeks), will begin the day following the initial ketamine infusion, and will be performed by a therapist who has successfully completed extensive training at the Beck Institute for Cognitive Therapy and Research and has experience with similar studies. Homework assignments will include thought records and activity charts which are used in standard practice to facilitate CBT interventions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ketamine/CBT Group
Arm Type
Experimental
Arm Description
Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Subjects will undergo a twice weekly two week course of IV infusions of ketamine
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy (CBT)
Intervention Description
Subjects will undergo twice weekly CBT for a total of 8 weeks
Primary Outcome Measure Information:
Title
Extinction Learning Task performance
Description
Hopkins Verbal Learning Test and extinction learning tasks will be administered both one week before and 24-hours after the first ketamine infusion and the change in scores compared.
Time Frame
24 hours Post ketamine infusion
Secondary Outcome Measure Information:
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Description
Change in MADRS from baseline through week eight using a random effects model
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: suffering from a depressive episode (DSM 5; either Major Depressive Disorder or Bipolar Disorder) and having failed one or more standard antidepressant treatments during the current episode; Age 18-65; Hamilton Depression Rating Scale (17-HAM-D) score of 21 or more prior to study entry. Exclusion Criteria: Any Axis I or Axis II Disorder, which at screening is clinically predominant to their depressive episode or has been predominant to their depressive episode at any time within 6 months prior to screening; Active suicidal thoughts with a plan; current or recent (<6 months ago) substance use disorder; Non-affective psychosis (such as schizophrenia or schizoaffective disorder); Pregnancy or breastfeeding; Inability to speak English fluently; A clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results; A history of CBT treatment in the past 12 months; Dementia; Delirium; Any other neurological or mental disease that might affect cognition or the ability to meaningfully participate in CBT. Untreated hypertension as defined by a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening on two of three measurements. Recent myocardial infarction (within one year) Syncopal event within the past year. Congestive heart failure (CHF) New York Heart Association Criteria >Stage 2 Angina pectoris. Heart rate <50 or >105 beats per minute at screening Females are eligible provided they meet criteria A or B below: Non-childbearing potential: e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening; or Childbearing potential, and meets the following criteria: i. Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent. ii. Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at enrollment prior to receiving study treatment. iii. Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Wilkinson, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Connecticut Mental Health Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
Yale Psychiatric Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

We'll reach out to this number within 24 hrs